6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine

Hemoglobinopathy Burden & Caribbean Genetics

Sickle cell disease (SCD) is an inherited disorder of hemoglobin synthesis caused by a single point mutation in the sixth codon of the beta-globin (HBB) gene on chromosome 11, resulting in the substitution of valine for glutamic acid ($\beta^6\text{Glu}\to\text{Val}$). When deoxygenated, the abnormal sickle hemoglobin (HbS) undergoes hydrophobic polymerization, forming rigid, insoluble intracellular polymers that distort erythrocytes into rigid, sickle-shaped forms. This molecular defect produces two primary pathological processes:

1. Chronic Intravascular & Extravascular Hemolysis: Shortens erythrocyte lifespan from 120 days to 10–20 days, resulting in chronic hemolytic anemia, hyperbilirubinemia, pigment gallstones, and endothelial nitric oxide scavenging by free plasma heme.
2. Microvascular Vaso-Occlusion: Adhesive interactions between sickled red cells, activated leukocytes, platelets, and the vascular endothelium produce microvascular occlusion, tissue ischemia, infarction, and intense inflammatory pain.

Clinical Genotypes in the West Indies

• HbSS (Sickle Cell Anemia): The homozygous state. Characterized by the most severe clinical course, marked baseline anemia (Hb 60–90 g/L), recurrent vaso-occlusive crises, and early functional autosplenectomy.
• HbSC Disease: Double heterozygosity for HbS and HbC (substitution of lysine for glutamic acid at codon 6). Patients have higher baseline hemoglobin levels (Hb 100–120 g/L), lower rates of early childhood crises, but heightened risk for proliferative sickle retinopathy and avascular necrosis of femoral and humeral heads in adulthood.
• HbS-$\beta^0$ Thalassemia: Clinically indistinguishable from severe HbSS, with microcytic red cell indices and an absence of normal HbA.
• HbS-$\beta^+$ Thalassemia: Retains partial production of normal beta-globin chains; characterized by a milder, variable clinical course and mild microcytic anemia.

The Caribbean Clinical Paradigm: The UWI Mona Sickle Cell Unit

The Caribbean has played a pioneering role in the global understanding of sickle cell disease. The Sickle Cell Unit (SCU) at the University of the West Indies (UWI) Mona campus in Kingston, Jamaica, established by Professor Graham Serjeant, founded the internationally recognized Jamaican Cohort Study. This landmark work proved that early universal neonatal screening, prophylactic oral penicillin V (administered from 2 months to at least 5 years of age), comprehensive pneumococcal vaccination (PCV13 and PPSV23), and structured parental education regarding abdominal palpation for splenic enlargement dramatically reduce early childhood mortality from encapsulated bacterial septicemia and acute splenic sequestration.

---

Acute Vaso-Occlusive Crisis (VOC): Assessment & Multimodal Analgesia

Acute painful vaso-occlusive crisis (VOC) is the most common reason for emergency room attendance and hospital admission in SCD. Ischemia within the bone marrow and microvasculature triggers severe, debilitating somatic and neuropathic pain, commonly affecting the lumbo-sacral spine, ribs, femurs, knees, and abdomen.

Emergency Triage & Analgesic Protocol

• Time-to-Analgesia Target: Acute VOC is an emergency. The first dose of parenteral analgesia must be administered within 30 minutes of triage arrival (the 'door-to-analgesia' standard).
• Step 1: Rapid Opioid Titration:
  • Administer parenteral intravenous Morphine 0.1 mg/kg (or subcutaneous morphine if IV access is difficult) immediately.
  • Re-evaluate pain score every 20 to 30 minutes; repeat titration doses (0.05–0.1 mg/kg) until pain is controlled.
  • Once initial control is established, use scheduled opioid dosing or individualized Patient-Controlled Analgesia (PCA), with regular pain, sedation and respiratory monitoring. A basal infusion is not automatic. Avoid relying solely on infrequent PRN doses during uncontrolled severe pain.
  • Avoid meperidine (pethidine) due to accumulation of its toxic metabolite, normeperidine, which induces seizures, dysphoria, and renal impairment.
• Step 2: Scheduled Non-Opioid Co-Analgesics:
  • Co-prescribe Paracetamol 1 g IV/oral every 6 hours regularly.
  • Add an NSAID (e.g. Ibuprofen 400 mg oral TDS or IV Ketorolac 15–30 mg 6-hourly) for up to 5 days, provided renal function, hydration, and platelet counts are normal.
• Step 3: Hydration Principles:
  • Patients with SCD possess a defect in renal medullary concentrating ability (hyposthenuria) and dehydrate rapidly.
  • Encourage oral fluids when tolerated and correct clinical dehydration. In euvolemic patients unable to drink, give IV fluid at no more than maintenance, with regular reassessment to avoid overload.
  • Caution: Overhydration is dangerous; excessive fluid administration dilutes oncotic pressure and precipitates pulmonary edema and acute chest syndrome.
• Step 4: Oxygen Therapy Caveat:
  • Administer supplemental oxygen ONLY if oxygen saturation (SpO2) is < 95% on room air (or drops below the patient's steady-state baseline).
  • In non-hypoxic patients, hyperoxia suppresses erythropoietin secretion, blunts reticulocyte production, and does not accelerate crisis resolution.

---

Acute Chest Syndrome (ACS)

Acute Chest Syndrome is the leading cause of premature death and ICU admission among adult and pediatric patients with SCD. It frequently arises 2 to 3 days following the onset of an acute vaso-occlusive bone crisis.

Diagnostic Criteria (Both Required):

1. New pulmonary infiltrate on chest radiography involving at least one complete lung segment; AND
2. At least one of the following signs or symptoms:
   • Fever (temperature >= 38.5°C)
   • Tachypnea, dyspnea, or wheezing
   • Pleuritic chest pain
   • Cough
   • Acute hypoxemia (SpO2 dropping > 3% below baseline or < 92% on room air)

Pathophysiology & Triggers

• Bone Marrow Fat Embolism: Necrosis of infarcted bone marrow during severe VOC releases fat droplets into the venous circulation, which lodge in the pulmonary microvasculature, causing acute endothelial inflammation and secretory phospholipase A2 activation.
• Infectious Pathogens: Atypical organisms (Mycoplasma pneumoniae, Chlamydia pneumoniae), bacterial pathogens (Streptococcus pneumoniae, Staphylococcus aureus), and respiratory viruses.
• In Situ Pulmonary Thromboembolism / Infarction: Local sickling within hypoventilated, atelectatic lung zones.

Comprehensive Management Protocol

• Broad-Spectrum Antibiotics: Intravenous third-generation cephalosporin (Ceftriaxone 2 g daily or Cefotaxime) PLUS an oral/IV macrolide (Azithromycin 500 mg daily or Clarithromycin) to cover both encapsulated pyogenic bacteria and atypical intracellular pathogens.
• Incentive Spirometry: Mandatory 10 deep breaths every 2 hours while awake. This simple mechanical maneuver prevents bibasilar atelectasis and reduces the progression of chest pain to full ACS by over 50%.
• Judicious Fluid Balance: Individualize oral and IV fluids to hydration, fluid balance and cardiopulmonary status; avoid fluid overload.
• Analgesia: Maintain effective pain control to allow deep breathing without causing hypoventilation or excessive sedation.
• Transfusion Strategy:
  • Simple Top-Up Transfusion: Indicated for mild-to-moderate ACS if hemoglobin has fallen significantly (> 15–20 g/L below baseline) and total Hb is < 90 g/L. Target post-transfusion hemoglobin of 100 g/L (10 g/dL). Do NOT transfuse above 100–110 g/L, as excessive red cell mass markedly elevates whole-blood viscosity and worsens vaso-occlusion.
  • Automated Red Blood Cell Exchange Transfusion (Erythrocytapheresis): Indicated for severe or rapidly deteriorating ACS: marked hypoxia ($SpO_2 < 90\%$ on supplemental oxygen or $PaO_2 < 60\text{ mmHg}$), multilobar consolidation, or progressive hemodynamic instability. Goal: rapidly reduce HbS concentration to < 30% while maintaining total hemoglobin at ~100 g/L without increasing hematocrit.

---

Differential Diagnosis of Acute Sickle Cell Crises

---

Disease-Modifying Therapy: Hydroxyurea (Hydroxycarbamide)

Hydroxyurea is the cornerstone disease-modifying oral pharmacotherapy in sickle cell disease.

• Mechanism of Action: Hydroxyurea is a ribonucleotide reductase inhibitor that stimulates the production of fetal hemoglobin (HbF). HbF does not sickle and directly inhibits the polymerization of deoxygenated HbS molecules within red cells. It also lowers circulating neutrophils, platelets, and vascular endothelial adhesion molecules, thereby reducing microvascular inflammation.
• Clinical Efficacy: Long-term administration reduces the frequency of acute painful VOC by 50%, reduces acute chest syndrome episodes, halves hospital admissions, and significantly prolongs overall survival.
• Indications: Offer hydroxyurea to children with HbSS or HbS-$\beta^0$ thalassemia from 9 months, regardless of clinical severity. Adult indications include recurrent moderate-to-severe pain, pain limiting daily activities, severe/recurrent ACS or severe symptomatic chronic anemia. Consult a sickle-cell specialist for other genotypes.
• Monitoring & Toxicities: Initial doses are commonly 15 mg/kg/day in adults and 20 mg/kg/day in children, with lower dosing in renal impairment. Check CBC, differential and reticulocytes at least every 4 weeks during dose adjustment, then every 2–3 months once stable. Titrate by protocol up to 35 mg/kg/day; myelosuppression requires dose interruption and reassessment. Counsel about reproductive risks and contraception.

---

Transfusion Medicine: Compatibility & Adverse Reactions

Extended Phenotype Matching in Sickle Cell Disease

Patients with SCD who receive repeated red cell transfusions have a high risk of developing red cell alloantibodies (occurring in 20% to 40% of recipients). This occurs primarily because of antigenic disparities between the predominantly Afro-Caribbean patient population and voluntary donor populations. To prevent alloimmunization, all SCD patients must receive extended phenotypic matching for:

• ABO and RhD;
• Extended Rh antigens: C, c, E, e;
• Kell antigen: K (K1).

Life-Threatening Transfusion Reactions

1. Acute Hemolytic Transfusion Reaction (AHTR):

   • Pathogenesis: Preformed recipient IgM antibodies (most commonly ABO incompatibility due to clerical identification error) bind donor RBCs, activating complement-mediated intravascular lysis.
   • Features: Fever, chills, severe flank/back pain, dyspnea, hypotension, hemoglobinuria ('red wine urine'), and rapid progression to DIC and acute renal failure.
   • Management: STOP THE TRANSFUSION IMMEDIATELY. Disconnect the blood set, preserve the IV access with fresh 0.9% normal saline, administer vigorous crystalloid diuresis (target urine output > 100–200 mL/h), administer IV furosemide, notify the blood bank, and return the implicated blood unit with post-transfusion patient blood and urine samples for direct antiglobulin testing (DAT/Coombs).

2. Delayed Hemolytic Transfusion Reaction & Hyperhemolysis Syndrome:

   • Occurs 5 to 14 days following transfusion due to an anamnestic response to minor red cell antigens (e.g. Duffy, Kidd, Kell).
   • In SCD, this can trigger Hyperhemolysis Syndrome: an acute, life-threatening destruction of BOTH the transfused donor cells AND the patient's own native erythrocytes. The post-transfusion hemoglobin falls to levels lower than the pre-transfusion baseline, accompanied by severe reticulocytopenia and dark urine. Transfusing additional red cells exacerbates hemolysis and can be fatal. Management requires high-dose intravenous Methylprednisolone and Intravenous Immunoglobulin (IVIG); avoid further transfusion unless life-threatening anemia makes it necessary, with urgent hematology/transfusion consultation and extended-matched red cells.

3. TRALI vs. TACO Differentiation:

   • Transfusion-Related Acute Lung Injury (TRALI): Non-cardiogenic pulmonary edema occurring within 6 hours of transfusion. Caused by donor anti-HLA or anti-neutrophil antibodies that activate recipient neutrophils in the pulmonary microcirculation, increasing vascular permeability. Characterized by acute hypoxemia, bilateral alveolar infiltrates, fever, and hypotension, with normal cardiac filling pressures and normal BNP.
   • Transfusion-Associated Circulatory Overload (TACO): Hydrostatic cardiogenic pulmonary edema caused by excessive volume or overly rapid transfusion in patients with underlying cardiac or renal compromise. Characterized by dyspnea, hypertension, jugular venous distension, S3 gallop, bilateral basilar crackles, and markedly elevated BNP / NT-proBNP, resolving promptly with intravenous loop diuretics (furosemide).